For the third time in 2018, the pharmaceutical company Lundbeck begins clinical trials with a brand new potential drug. It is another self-developed drug, which makes Executive Vice President at Lundbeck, Anders Gersel Pedersen, reject criticism against the company's pipeline.
Lars Fogh Iversen, who was recently put in charge of Novo Nordisk's internal research, has been very involved in the company's work to develop a tablet version of the GLP-1 molecule semaglutide. But when the project began more than ten years ago, it did not look very promising and it would not have happened without teamwork across the organization, he says.
Drugs against hearing loss are moving closer and may eventually become a competitor to the established hearing aid companies. A fully developed drug still has long prospects, however, companies such as GN Hearing and William Demant should keep an eye on the development.
Danish company Reapplix has presented new, good data for a biological patch that heals diabetic foot ulcers, and the company has therefore established a subsidiary in the US, which will be in charge of launching the product on the US market. At the same time, the company has hired a CFO and has secured more funding from its investors, including Novo Holdings, Seed Capital and Vækstfonden.
After a busy spring, the new Novo-financed Bioinnovation Institute is ready to bring in the first projects and reveal how the institute's entrepreneurial initiatives have been structured - it will happen this fall, says Director.
On Tuesday morning, the first shares in biotech company Virogates were traded on the Copenhagen Stock Exchange. It was celebrated at an event, where spirits were high and the excitement obvious.
According to Genmab, the biotech company's partner Janssen does not intend to begin a new study in Japan with the company's golden egg Darzalex and an experimental PD-1 inhibitor, as was otherwise reported by the website clinicaltrials.gov.
Danish daily Berlingske's 2018 list of the 100 most powerful people in Denmark includes six Novo Nordisk executives. The remainder of this list shows an underrepresentation from the Danish life science sector – only one other medico boss appears.
Gubra has received a research grant from diabetes organization JDRF in order to develop a new type of insulin with the potential to revolutionize the treatment of type 1 diabetes and make other types of insulin obsolete. According to CSO Keld Fosgerau, the project can be expanded to maximize value before getting a partner on board.
One of the world's most profitable hedge funds, Renaissance Technologies, owns around DKK 5 billion (EUR 671 million) in Novo Nordisk equities. The hedge fund's initial investment in Novo Nordisk was made in 2005. The fund also owns equities in only one other Danish biotech compnay.
A series of Danish life science companies will head to Italy in November, where they alongside the Royal family will create awareness of Danish products.
VP at Ferrosan Medical Devices is the first recipient of a new grant aimed at promoting women role models in the field of Life Sciences. A headhunter company was behind the award.
Medico company Vingmed Danmark has, after 30 years of independence, been sold to its former owners, who as part of the acquisition merges its Danish subsidiaries. The goal is to create a stronger Nordic player in the medico sector, say the new owners.
